Format

Send to

Choose Destination
Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41.

Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.

Author information

1
Hull York Medical School, University of York, Heslington, York, UK. charles.lacey@hyms.ac.uk

Abstract

Human Papillomavirus (HPV)-6 and -11 are the causative agents of ano-genital warts (GWs) and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are uncommonly found in malignant lesions. GWs are an extremely prevalent sexually transmitted disease, whereas RRP is a rare disease that can be life threatening and requires multiple surgical procedures. GWs and RRP cause substantial healthcare costs. A quadrivalent HPV-6/11/16/18 vaccine (Merck/SPMSD) has shown essentially 100% protection against GWs in women in early studies. Cost-effectiveness analyses are needed to assess the benefits of the HPV-6/11 virus-like particle (VLP) components of the quadrivalent vaccine in population-based vaccination programmes.

PMID:
16950016
DOI:
10.1016/j.vaccine.2006.06.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center